Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $98,383 | 35 | 85.3% |
| Travel and Lodging | $9,777 | 42 | 8.5% |
| Unspecified | $5,370 | 1 | 4.7% |
| Food and Beverage | $1,700 | 26 | 1.5% |
| Education | $164.45 | 1 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $57,996 | 48 | $0 (2023) |
| Janssen Research & Development, LLC | $15,573 | 6 | $0 (2020) |
| Merck Sharp & Dohme LLC | $8,339 | 11 | $0 (2023) |
| ITI, Inc. | $6,550 | 3 | $0 (2020) |
| Eli Lilly and Company | $6,419 | 13 | $0 (2023) |
| GlaxoSmithKline, LLC. | $5,870 | 3 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $4,295 | 6 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $2,954 | 1 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $1,902 | 5 | $0 (2019) |
| Boehringer Ingelheim International GmbH | $1,500 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $12,678 | 16 | Amgen Inc. ($7,586) |
| 2022 | $8,536 | 5 | Amgen Inc. ($5,355) |
| 2021 | $3,675 | 2 | GlaxoSmithKline, LLC. ($2,925) |
| 2020 | $26,442 | 10 | ITI, Inc. ($6,550) |
| 2019 | $32,692 | 33 | Amgen Inc. ($19,006) |
| 2018 | $16,297 | 20 | Amgen Inc. ($12,278) |
| 2017 | $15,074 | 19 | Amgen Inc. ($7,446) |
All Payment Transactions
105 individual payment records from CMS Open Payments — Page 5 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/29/2017 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 08/22/2017 | Ironwood Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $1,075.00 | General |
| 04/19/2017 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 04/19/2017 | Amgen Inc. | — | Food and Beverage | Cash or cash equivalent | $24.07 | General |
| 04/19/2017 | Amgen Inc. | — | Travel and Lodging | Cash or cash equivalent | $15.10 | General |
About Dr. David Kass, M.D
Dr. David Kass, M.D is a Cardiovascular Disease healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588605877.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Kass, M.D has received a total of $115,394 in payments from pharmaceutical and medical device companies, with $12,678 received in 2023. These payments were reported across 105 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($98,383).
Practice Information
- Specialty Cardiovascular Disease
- Location Baltimore, MD
- Active Since 06/09/2006
- Last Updated 02/08/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1588605877
Products in Payments
- CAPLYTA (Drug) $6,550
- MK-1242 (Drug) $5,650
- Parsabiv (Biological) $5,092
- NO PRODUCT DISCUSSED (Drug) $1,902
- Moderna Covid-19 Vaccine (Biological) $750.00
- VERQUVO (Drug) $500.00
- INVOKANA (Drug) $181.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Baltimore
Dr. Navin Kapur, M.d, M.D
Cardiovascular Disease — Payments: $1.8M
Sanjay Rajagopalan, Md, MD
Cardiovascular Disease — Payments: $572,017
Dr. Michael Blaha, M.d., Mph, M.D., MPH
Cardiovascular Disease — Payments: $569,288
Hugh Calkins, M.d, M.D
Cardiovascular Disease — Payments: $387,473
Dr. Charles Cummings, M.d, M.D
Cardiovascular Disease — Payments: $337,057
Dr. Charles Love, M.d, M.D
Cardiovascular Disease — Payments: $327,551